 | • レポートコード：GIR-107A11930 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、NSCLC用標的薬ALK阻害剤のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。NSCLC用標的薬ALK阻害剤の種類別市場規模（クリゾチニブ、セリチニブ、アレクチニブ、ブリガチニブ、ロルラチニブ、その他）、用途別市場規模（NSCLC扁平上皮がん、NSCLC腺がん、NSCLC大細胞がん）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・NSCLC用標的薬ALK阻害剤の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Novartis、Chugai Pharmaceutical (Hoffmann-La Roche group)、ARIAD Pharmaceuticals (Takeda)、Genvio Pharma Limited、Beacon Pharma Limited、Drug International Limted、Incepta Pharmaceuticals ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：クリゾチニブ、セリチニブ、アレクチニブ、ブリガチニブ、ロルラチニブ、その他 ・用途別分析2016年-2026年：NSCLC扁平上皮がん、NSCLC腺がん、NSCLC大細胞がん ・NSCLC用標的薬ALK阻害剤の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・NSCLC用標的薬ALK阻害剤のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・NSCLC用標的薬ALK阻害剤のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・NSCLC用標的薬ALK阻害剤の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・NSCLC用標的薬ALK阻害剤の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Targeted Drug ALK Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Targeted Drug ALK Inhibitors for NSCLC size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Targeted Drug ALK Inhibitors for NSCLC market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Targeted Drug ALK Inhibitors for NSCLC market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Crizotinib
Ceritinib
Alectinib
Brigatinib
Lorlatinib
Other
Market segment by Application, can be divided into
Squamous Cell Carcinoma of NSCLC
Adenocarcinoma of NSCLC
Large Cell Carcinoma of NSCLC
Market segment by players, this report covers
Pfizer
Novartis
Chugai Pharmaceutical (Hoffmann-La Roche group)
ARIAD Pharmaceuticals (Takeda)
Genvio Pharma Limited
Beacon Pharma Limited
Drug International Limted
Incepta Pharmaceuticals
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Targeted Drug ALK Inhibitors for NSCLC
1.2 Classification of Targeted Drug ALK Inhibitors for NSCLC by Type
1.2.1 Overview: Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type in 2020
1.2.3 Crizotinib
1.2.4 Ceritinib
1.2.5 Alectinib
1.2.6 Brigatinib
1.2.7 Lorlatinib
1.2.8 Other
1.3 Global Targeted Drug ALK Inhibitors for NSCLC Market by Application
1.3.1 Overview: Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Squamous Cell Carcinoma of NSCLC
1.3.3 Adenocarcinoma of NSCLC
1.3.4 Large Cell Carcinoma of NSCLC
1.4 Global Targeted Drug ALK Inhibitors for NSCLC Market Size & Forecast
1.5 Global Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast by Region
1.5.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region, (2016-2021)
1.5.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.4 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.6 South America Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Targeted Drug ALK Inhibitors for NSCLC Market Drivers
1.6.2 Targeted Drug ALK Inhibitors for NSCLC Market Restraints
1.6.3 Targeted Drug ALK Inhibitors for NSCLC Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.1.4 Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.2.4 Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
2.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Details
2.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Major Business
2.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Developments and Future Plans
2.4 ARIAD Pharmaceuticals (Takeda)
2.4.1 ARIAD Pharmaceuticals (Takeda) Details
2.4.2 ARIAD Pharmaceuticals (Takeda) Major Business
2.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.4.4 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans
2.5 Genvio Pharma Limited
2.5.1 Genvio Pharma Limited Details
2.5.2 Genvio Pharma Limited Major Business
2.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.5.4 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Genvio Pharma Limited Recent Developments and Future Plans
2.6 Beacon Pharma Limited
2.6.1 Beacon Pharma Limited Details
2.6.2 Beacon Pharma Limited Major Business
2.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.6.4 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Beacon Pharma Limited Recent Developments and Future Plans
2.7 Drug International Limted
2.7.1 Drug International Limted Details
2.7.2 Drug International Limted Major Business
2.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.7.4 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Drug International Limted Recent Developments and Future Plans
2.8 Incepta Pharmaceuticals
2.8.1 Incepta Pharmaceuticals Details
2.8.2 Incepta Pharmaceuticals Major Business
2.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
2.8.4 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Incepta Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Targeted Drug ALK Inhibitors for NSCLC Players Market Share
3.2.2 Top 10 Targeted Drug ALK Inhibitors for NSCLC Players Market Share
3.2.3 Market Competition Trend
3.3 Targeted Drug ALK Inhibitors for NSCLC Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Market Share by Type (2016-2021)
4.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application (2016-2021)
5.2 Targeted Drug ALK Inhibitors for NSCLC Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2026)
6.2 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2026)
6.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
6.3.1 North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2016-2026)
6.3.2 United States Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
6.3.3 Canada Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
6.3.4 Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2026)
7.2 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2026)
7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
7.3.1 Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2016-2026)
7.3.2 Germany Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.3 France Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.5 Russia Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
7.3.6 Italy Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2026)
8.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2026)
8.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region
8.3.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Region (2016-2026)
8.3.2 China Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.3 Japan Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.4 South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.5 India Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
8.3.7 Australia Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2026)
9.2 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2026)
9.3 South America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
9.3.1 South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2016-2026)
9.3.2 Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
9.3.3 Argentina Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2026)
10.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2026)
10.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
10.3.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2016-2026)
10.3.2 Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
10.3.4 UAE Targeted Drug ALK Inhibitors for NSCLC Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Targeted Drug ALK Inhibitors for NSCLC Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) by Region (2016-2021)
Table 5. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 9. Pfizer Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Novartis Corporate Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 13. Novartis Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Chugai Pharmaceutical (Hoffmann-La Roche group) Corporate Information, Head Office, and Major Competitors
Table 15. Chugai Pharmaceutical (Hoffmann-La Roche group) Major Business
Table 16. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 17. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. ARIAD Pharmaceuticals (Takeda) Corporate Information, Head Office, and Major Competitors
Table 19. ARIAD Pharmaceuticals (Takeda) Major Business
Table 20. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 21. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Genvio Pharma Limited Corporate Information, Head Office, and Major Competitors
Table 23. Genvio Pharma Limited Major Business
Table 24. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 25. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Beacon Pharma Limited Corporate Information, Head Office, and Major Competitors
Table 27. Beacon Pharma Limited Major Business
Table 28. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 29. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Drug International Limted Corporate Information, Head Office, and Major Competitors
Table 31. Drug International Limted Major Business
Table 32. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 33. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Incepta Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 35. Incepta Pharmaceuticals Major Business
Table 36. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product and Solutions
Table 37. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) by Players (2019-2021)
Table 39. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players (2019-2021)
Table 40. Breakdown of Targeted Drug ALK Inhibitors for NSCLC by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Targeted Drug ALK Inhibitors for NSCLC Players Head Office, Products and Services Provided
Table 42. Targeted Drug ALK Inhibitors for NSCLC Mergers & Acquisitions in the Past Five Years
Table 43. Targeted Drug ALK Inhibitors for NSCLC New Entrants and Expansion Plans
Table 44. Global Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) by Type (2016-2021)
Table 45. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type (2016-2021)
Table 46. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Forecast by Type (2021-2026)
Table 47. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2021)
Table 48. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Forecast by Application (2021-2026)
Table 49. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Targeted Drug ALK Inhibitors for NSCLC Picture
Figure 2. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type in 2020
Figure 3. Crizotinib
Figure 4. Ceritinib
Figure 5. Alectinib
Figure 6. Brigatinib
Figure 7. Lorlatinib
Figure 8. Other
Figure 9. Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Application in 2020
Figure 10. Squamous Cell Carcinoma of NSCLC Picture
Figure 11. Adenocarcinoma of NSCLC Picture
Figure 12. Large Cell Carcinoma of NSCLC Picture
Figure 13. Global Targeted Drug ALK Inhibitors for NSCLC Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 14. Global Targeted Drug ALK Inhibitors for NSCLC Revenue and Forecast (2016-2026) & (USD Million)
Figure 15. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)
Figure 16. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Region in 2020
Figure 17. North America Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. South America Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. Targeted Drug ALK Inhibitors for NSCLC Market Drivers
Figure 23. Targeted Drug ALK Inhibitors for NSCLC Market Restraints
Figure 24. Targeted Drug ALK Inhibitors for NSCLC Market Trends
Figure 25. Pfizer Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Developments and Future Plans
Figure 28. ARIAD Pharmaceuticals (Takeda) Recent Developments and Future Plans
Figure 29. Genvio Pharma Limited Recent Developments and Future Plans
Figure 30. Beacon Pharma Limited Recent Developments and Future Plans
Figure 31. Drug International Limted Recent Developments and Future Plans
Figure 32. Incepta Pharmaceuticals Recent Developments and Future Plans
Figure 33. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players in 2020
Figure 34. Targeted Drug ALK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 35. Global Top 3 Players Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share in 2020
Figure 36. Global Top 10 Players Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share in 2020
Figure 37. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 38. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Type in 2020
Figure 39. Global Targeted Drug ALK Inhibitors for NSCLC Market Share Forecast by Type (2021-2026)
Figure 40. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application in 2020
Figure 41. Global Targeted Drug ALK Inhibitors for NSCLC Market Share Forecast by Application (2021-2026)
Figure 42. North America Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 43. North America Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 44. North America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 45. United States Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 49. Europe Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 50. Europe Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 51. Germany Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 57. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Region (2016-2026)
Figure 59. China Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South Korea Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 66. South America Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 67. South America Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Type (2016-2026)
Figure 71. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Sales Market Share by Application (2016-2026)
Figure 72. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. UAE Targeted Drug ALK Inhibitors for NSCLC Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Methodology
Figure 77. Research Process and Data Source
世界のNSCLC用標的薬物MEK阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug MEK Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization…- 世界のNSCLC用標的薬VEGFR2阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug VEGFR2 Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…
- 世界のNSCLC用標的薬BRAF阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug BRAF Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 世界のNSCLC用標的薬VEGF阻害剤市場 2021：企業別、地域別、種類・用途別 The Targeted Drug VEGF Inhibitors for NSCLC market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizatio…
- 世界の多発性骨髄腫用標的薬市場 2021：企業別、地域別、種類・用途別 The Targeted Drugs for Multiple Myeloma market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…